STOCK TITAN

SELLAS Life Sciences prices $150M stock offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

SELLAS Life Sciences Group, Inc. priced an underwritten public offering of 11,538,462 shares of common stock at a public offering price of $13.00 per share. The company also granted underwriters a 30-day option to purchase up to 1,730,769 additional shares at the same price.

The company expects approximately $161.8 million in net proceeds, including full exercise of the option, after underwriting discounts, commissions and estimated offering expenses. The press release states gross proceeds of $150.0 million before deductions. The offering is expected to close on or about November 20, 2026, subject to customary closing conditions.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Offering shares 11,538,462 shares Common stock in the underwritten public offering.
Public offering price $13.00 per share Price for the offering shares and option shares.
Gross proceeds $150.0 million Stated before underwriting discounts, commissions and offering expenses.
Option shares Up to 1,730,769 shares Underwriters' option to purchase additional common shares.
Underwriters' option period 30 days Option to purchase additional shares.
Expected net proceeds Approximately $161.8 million Includes full exercise of the option and is after underwriting discounts, commissions and estimated offering expenses.
underwritten public offering financial
"pricing of the underwritten public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
underwriting discounts and commissions financial
"after deducting underwriting discounts and commissions"
Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.
shelf registration statement regulatory
"pursuant to a shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"a final prospectus supplement filed with the Commission"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SLS shares are being offered and at what price?

SELLAS priced 11,538,462 common shares at $13.00 per share, and granted underwriters a 30-day option to purchase up to 1,730,769 additional shares at the same price.

What proceeds does SELLAS expect from the SLS offering?

The company expects approximately $161.8 million in net proceeds, including full exercise of the underwriters’ option, after underwriting discounts, commissions and estimated offering expenses. The press release states gross proceeds of $150.0 million before deductions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001390478 0001390478 2026-11-18 2026-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): November 18, 2026

 

 

 

SELLAS Life Sciences Group, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33958   20-8099512
(State or other jurisdiction of
incorporation or organization)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)
         
    7 Times Square, Suite 2503
New York, NY 10036
   
    (Address of Principal Executive
Offices) (Zip Code)
   
         
Registrant’s telephone number, including area code: (646) 200-5278

 

 

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per share SLS The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 18, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of 11,538,462 shares (the “Offering Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a price to public of $13.00 per share. In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 1,730,769 additional shares of Common Stock on the same terms as the Offering Shares (the “Option Shares” and, together with the Offering Shares, the “Shares”).

 

The Company expects to receive net proceeds from the offering of approximately $161.8 million, which includes the proceeds from the Underwriters’ exercise in full of their option to purchase the Option Shares, after deducting underwriting discounts and commissions and estimated offering expenses.

 

The offering of the Shares is being made pursuant to the Company’s shelf registration statement on Form S-3 (Registration Statement No. 333-294504) that was previously filed with the Securities and Exchange Commission (the “Commission”) on March 20, 2026, which became automatically effective upon filing (the “Registration Statement”), as supplemented by a final prospectus supplement filed with the Commission on November 19, 2026. The offering is expected to close on or about November 20, 2026, subject to the satisfaction of customary closing conditions. This Current Report on Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy any of the Shares.

 

A copy of the legal opinion and consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. relating to the validity of the issuance and sale of the Shares is attached as Exhibit 5.1 hereto.

 

The Underwriting Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination provisions. The Underwriting Agreement provides for indemnification by the Underwriters of the Company, its directors and certain of its executive officers, and by the Company of the Underwriters, for certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, and affords certain rights of contribution with respect thereto. The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, which is attached as Exhibit 1.1 hereto and incorporated by reference herein.

 

 

ITEM 8.01 Other Events.

 

On November 18, 2026, the Company issued a press release announcing the pricing of the underwritten public offering, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

ITEM 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

     
Exhibit
Number
  Description
     
1.1   Underwriting Agreement, dated November 18, 2026, by and among the Company and J.P. Morgan Securities LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein.
     
5.1   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
     
23.1   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (contained in Exhibit 5.1).
     
99.1   Press Release of SELLAS Life Sciences Group, Inc., dated November 18, 2026.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SELLAS Life Sciences Group, Inc.
       
Date: November 20, 2026 By: /s/ John T. Burns
      Name: John T. Burns
      Title: Senior Vice President, Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering

 

NEW YORK, November 18, 2026 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $150.0 million before deducting underwriting discounts and commissions and offering expenses. In addition, SELLAS has also granted the underwriters a 30-day option to purchase up to 1,730,769 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 20, 2026, subject to the satisfaction of customary closing conditions.

 

J.P. Morgan and TD Cowen are acting as the lead book-running managers for the offering. Mizuho is also acting as a book-running manager for the offering. A.G.P./Alliance Global Partners and Maxim Group LLC are acting as lead managers for the offering.

 

The public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-294504) that was previously filed with the Securities and Exchange Commission (the “SEC”) on March 20, 2026, and became automatically effective upon filing. The preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC, and a final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com.

 

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

 

About SELLAS Life Sciences Group, Inc.

 

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib), a small molecule CDK9 inhibitor, for the treatment of AML in patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the expected closing of the public offering. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the public offering, as well as risks and uncertainties inherent in SELLAS’ business, including those described in the company’s periodic filings with the SEC. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

 

Investor Contact

 

John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

 

Media Contact

 

Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
jbosisio@simpsonhealthcare.com

 

Source: SELLAS Life Sciences Group, Inc.

 

 

 

Filing Exhibits & Attachments

6 documents

Keep reading